PF-Neostigmine Methylsulfate Injection, USP 3 mg/3 mL (1 mg/mL) vial, Rx Only, Nephron 503B Outso...
FDA Drug Recall #D-0065-2023 — Class II — November 10, 2022
Recall Summary
| Recall Number | D-0065-2023 |
| Classification | Class II — Moderate risk |
| Date Initiated | November 10, 2022 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Nephron Sterile Compounding Center LLC |
| Location | West Columbia, SC |
| Product Type | Drugs |
| Quantity | 56,220 vials |
Product Description
PF-Neostigmine Methylsulfate Injection, USP 3 mg/3 mL (1 mg/mL) vial, Rx Only, Nephron 503B Outsourcing Facility 4500 12th Street Extension West Columbia, SC 29172, NDC 69374-932-33, UPC 3 69374-93233 2.
Reason for Recall
CGMP Deviations: Potential for cross contamination due to product carry over.
Distribution Pattern
Nationwide in the USA
Lot / Code Information
Lots: NE1062A, NE1062B Exp. 12/02/2022; NE1065A, NE1065B Exp. 12/13/2022; NE2011A, NE2011B Exp. 03/15/2022.
Other Recalls from Nephron Sterile Compounding Center LLC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0257-2025 | Class II | Sodium Chloride Injection 9%, USP, 500 mL, Sing... | Feb 10, 2025 |
| D-0358-2023 | Class II | Norepinephrine Bitartrate in 0.9% Sodium Chlori... | Feb 22, 2023 |
| D-0360-2023 | Class II | Phenylephrine HCl Injection, USP, 0.4 mg/10 mL ... | Feb 22, 2023 |
| D-0355-2023 | Class II | Diltiazem HCl in 0.7% Sodium Chloride Injection... | Feb 22, 2023 |
| D-0359-2023 | Class II | Phenylephrine HCl Injection, USP, 1 mg/10 mL (1... | Feb 22, 2023 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.